Edwards Lifesciences Lowers Tariff Impact Forecast, Keeps Gross Margin Guidance Intact
The company reaffirmed its guidance for adjusted gross profit margin for the full year 2025 to remain within the original range of 78% to 79%. Chief financial officer Scott Ullem attributed this to currency and tariff dynamics.